PL2125011T3 - Stymulacja odpowiedzi immunologicznej przez lipidy kationowe - Google Patents
Stymulacja odpowiedzi immunologicznej przez lipidy kationoweInfo
- Publication number
- PL2125011T3 PL2125011T3 PL08799629T PL08799629T PL2125011T3 PL 2125011 T3 PL2125011 T3 PL 2125011T3 PL 08799629 T PL08799629 T PL 08799629T PL 08799629 T PL08799629 T PL 08799629T PL 2125011 T3 PL2125011 T3 PL 2125011T3
- Authority
- PL
- Poland
- Prior art keywords
- stimulation
- immune response
- cationic lipids
- lipids
- cationic
- Prior art date
Links
- 125000002091 cationic group Chemical group 0.000 title 1
- 230000028993 immune response Effects 0.000 title 1
- 230000000638 stimulation Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
- A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C219/00—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton
- C07C219/02—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C219/04—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C219/06—Compounds containing amino and esterified hydroxy groups bound to the same carbon skeleton having esterified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having the hydroxy groups esterified by carboxylic acids having the esterifying carboxyl groups bound to hydrogen atoms or to acyclic carbon atoms of an acyclic saturated carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89641207P | 2007-03-22 | 2007-03-22 | |
| US91154907P | 2007-04-13 | 2007-04-13 | |
| US94851207P | 2007-07-09 | 2007-07-09 | |
| US98379907P | 2007-10-30 | 2007-10-30 | |
| US12/049,957 US8877206B2 (en) | 2007-03-22 | 2008-03-17 | Stimulation of an immune response by cationic lipids |
| PCT/US2008/057678 WO2008116078A2 (en) | 2007-03-22 | 2008-03-20 | Stimulation of an immune response by cationic lipids |
| EP08799629.4A EP2125011B1 (en) | 2007-03-22 | 2008-03-20 | Stimulation of an immune response by cationic lipids |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2125011T3 true PL2125011T3 (pl) | 2016-05-31 |
Family
ID=39766768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL08799629T PL2125011T3 (pl) | 2007-03-22 | 2008-03-20 | Stymulacja odpowiedzi immunologicznej przez lipidy kationowe |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8877206B2 (pl) |
| EP (1) | EP2125011B1 (pl) |
| JP (2) | JP2010522206A (pl) |
| CN (2) | CN107670031A (pl) |
| AU (1) | AU2008228798B2 (pl) |
| EA (1) | EA200901270A1 (pl) |
| ES (1) | ES2562714T3 (pl) |
| PL (1) | PL2125011T3 (pl) |
| TW (1) | TWI558412B (pl) |
| WO (1) | WO2008116078A2 (pl) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002038175A1 (en) | 2000-11-07 | 2002-05-16 | Immunovaccine Technologies Inc. | Vaccines with enhanced immune response and methods for their preparation |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| ES2588705T3 (es) | 2007-09-27 | 2016-11-04 | Immunovaccine Technologies Inc. | Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo |
| US20100209452A1 (en) * | 2007-10-03 | 2010-08-19 | Immunovaccine Technologies, Inc | Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof |
| AU2009236306B2 (en) | 2008-04-17 | 2015-04-02 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| ES2524561T3 (es) * | 2008-05-06 | 2014-12-10 | Colgate-Palmolive Company | Método de medición de los efectos de los componentes en la producción de especies reactivas del oxígeno en las células |
| CA2723918C (en) | 2008-06-05 | 2018-01-09 | Immunovaccine Technologies Inc. | Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance |
| JP2011184344A (ja) * | 2010-03-08 | 2011-09-22 | Kao Corp | ｐ２１発現促進剤 |
| HUE047796T2 (hu) | 2010-07-06 | 2020-05-28 | Glaxosmithkline Biologicals Sa | RNS bevitele több immunútvonal bekapcsolására |
| DK2590676T3 (en) | 2010-07-06 | 2016-10-24 | Glaxosmithkline Biologicals Sa | Virionlignende feed particles to self-replicating RNA molecules |
| JP5940064B2 (ja) | 2010-07-06 | 2016-06-29 | ノバルティス アーゲー | 低用量のｒｎａを用いた大型哺乳動物の免疫化 |
| NZ606591A (en) | 2010-07-06 | 2015-02-27 | Novartis Ag | Cationic oil-in-water emulsions |
| RS54489B1 (sr) | 2010-07-06 | 2016-06-30 | Glaxosmithkline Biologicals Sa | Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk |
| HRP20221048T1 (hr) | 2010-08-31 | 2022-11-11 | Glaxosmithkline Biologicals Sa | Mali liposomi za isporuku rna koja kodira imunogen |
| SMT202200311T1 (it) | 2010-08-31 | 2022-09-14 | Glaxosmithkline Biologicals Sa | Liposomi pegilati per somministrare rna codificante un immunogene |
| EP3520813B1 (en) | 2010-10-11 | 2023-04-19 | GlaxoSmithKline Biologicals S.A. | Antigen delivery platforms |
| HRP20250981T1 (hr) | 2011-05-24 | 2025-10-24 | BioNTech SE | Individualizirana cjepiva protiv raka |
| EP3456316A1 (en) | 2011-07-06 | 2019-03-20 | GlaxoSmithKline Biologicals S.A. | Cationic oil-in-water emulsions |
| CN103781470A (zh) | 2011-07-06 | 2014-05-07 | 诺华股份有限公司 | 包含核酸的水包油乳液 |
| EP3854413A1 (en) | 2011-07-06 | 2021-07-28 | GlaxoSmithKline Biologicals SA | Immunogenic combination compositions and uses thereof |
| ES2689799T3 (es) * | 2011-09-12 | 2018-11-15 | Pds Biotechnology Corporation | Formulaciones de vacunas particuladas |
| IN2014CN02581A (pl) | 2011-10-06 | 2015-08-07 | Immunovaccine Technologies Inc | |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| AU2013274235B2 (en) | 2012-06-15 | 2018-01-18 | Samir N. Khleif | Cationic lipid vaccine compositions and methods of use |
| AU2013317805B2 (en) | 2012-09-21 | 2018-07-26 | Pds Biotechnology Corporation | Improved vaccine compositions and methods of use |
| EP2925348B1 (en) | 2012-11-28 | 2019-03-06 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2015018943A2 (en) * | 2013-08-08 | 2015-02-12 | Institut Pasteur | Correlation of disease activity with clonal expansions of human papillomavirus 16-specific cd8+ t-cells in patients with severe erosive oral lichen planus |
| RU2021109685A (ru) | 2014-04-23 | 2021-04-13 | МОДЕРНАТиЭкс, ИНК. | Вакцины на основе нуклеиновых кислот |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| BR112018008090A2 (pt) * | 2015-10-22 | 2018-11-13 | Modernatx Inc | vacina de vírus do herpes simplex. |
| JP2019500021A (ja) * | 2015-11-13 | 2019-01-10 | ピーディーエス バイオテクノロジー コーポレイションＰｄｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 樹状細胞療法においてｅｘ ｖｉｖｏでの抗原のプロセシングと提示を亢進させるための合成ベクターとしての脂質 |
| US11612652B2 (en) * | 2015-11-13 | 2023-03-28 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
| WO2017186711A1 (en) | 2016-04-25 | 2017-11-02 | Invivogen | Novel complexes of immunostimulatory compounds, and uses thereof |
| WO2018067822A1 (en) * | 2016-10-05 | 2018-04-12 | Pds Biotechnology Corporation | Methods to alter the tumor microenvironment for effective cancer immunotherapy |
| CA3041307A1 (en) | 2016-10-21 | 2018-04-26 | Giuseppe Ciaramella | Human cytomegalovirus vaccine |
| US11752206B2 (en) | 2017-03-15 | 2023-09-12 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| CN111655238A (zh) | 2017-12-05 | 2020-09-11 | Pds生物科技公司 | 用于刺激i型干扰素基因的包括阳离子脂质的方法和组合物 |
| JP7385206B2 (ja) * | 2018-12-04 | 2023-11-22 | 国立大学法人大阪大学 | 免疫賦活剤 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4247493A4 (en) * | 2020-11-20 | 2024-10-09 | PDS Biotechnology Corporation | METHODS AND COMPOSITIONS CONTAINING CATIONIC LIPIDS FOR IMMUNOTHERAPY BY DIRECT TUMOR INJECTION |
| AU2023364999A1 (en) * | 2022-10-17 | 2025-05-22 | Pds Biotechnology Corporation | Novel non-HLA restricted T cell TCR gamma alternate reading frame protein (TARP) compositions and uses thereof |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2167480A (en) | 1927-11-02 | 1939-07-25 | Rca Corp | Signaling |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| US5703055A (en) * | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US6214804B1 (en) * | 1989-03-21 | 2001-04-10 | Vical Incorporated | Induction of a protective immune response in a mammal by injecting a DNA sequence |
| US5264618A (en) * | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| US6183745B1 (en) | 1990-12-12 | 2001-02-06 | The University Of Queensland | Subunit papilloma virus vaccine and peptides for use therein |
| WO1993003709A1 (en) | 1991-08-16 | 1993-03-04 | Vical, Inc. | Composition and method for treating cystic fibrosis |
| US6419931B1 (en) * | 1991-08-26 | 2002-07-16 | Epimmune Inc. | Compositions and methods for eliciting CTL immunity |
| JP3738395B2 (ja) | 1991-08-26 | 2006-01-25 | エピミューン，インコーポレイティド | Ｈｌａ−制限型ｂ型肝炎ウィルスのｃｔｌエピトープ |
| US5283185A (en) * | 1991-08-28 | 1994-02-01 | University Of Tennessee Research Corporation | Method for delivering nucleic acids into cells |
| IL105554A (en) | 1992-05-05 | 1999-08-17 | Univ Leiden | Peptides of human papillomavirus for use in preparations elicit a human T cell response |
| CA2134773A1 (en) * | 1992-06-04 | 1993-12-09 | Robert J. Debs | Methods and compositions for in vivo gene therapy |
| US7105574B1 (en) * | 1999-03-26 | 2006-09-12 | Vical Incorporated | Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines |
| US5334761A (en) * | 1992-08-28 | 1994-08-02 | Life Technologies, Inc. | Cationic lipids |
| US9266930B1 (en) | 1993-03-05 | 2016-02-23 | Epimmune Inc. | Inducing cellular immune responses to Plasmodium falciparum using peptide and nucleic acid compositions |
| AU702517B2 (en) | 1993-08-06 | 1999-02-25 | Epimmune, Inc. | Cloning and characterization of the complete MAGE-1 gene |
| AUPM500494A0 (en) * | 1994-04-12 | 1994-05-05 | Minister For Agriculture & Rural Affairs For The State Of New South Wales, The | Composition for use in increasing mucosal immunity |
| FR2726764B1 (fr) * | 1994-11-14 | 1997-01-31 | Pasteur Merieux Serums Vacc | Adjuvant pour composition vaccinale |
| US6008202A (en) * | 1995-01-23 | 1999-12-28 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| FR2732895B1 (fr) * | 1995-04-11 | 1997-05-16 | Pasteur Merieux Serums Vacc | Utilisation d'un compose amphipathique cationique comme agent de transfection, comme adjuvant de vaccin, ou comme medicament |
| EP0840622A4 (en) | 1995-07-21 | 2003-01-02 | Aventis Pharma Inc | ADENO-ASSOCIATED VIRUS LIPOSOMES AND THEIR USE FOR THE TRANSFECTION OF DENDRITIC CELLS FOR THE STIMULATION OF SPECIFIC IMMUNITY |
| JP2001503735A (ja) * | 1996-07-03 | 2001-03-21 | ユニバーシティ オブ ピッツバーグ | 親水性活性試薬のためのエマルジョン処方物 |
| US7001614B2 (en) * | 1996-08-19 | 2006-02-21 | The United States Of America As Represented By The Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US7288266B2 (en) * | 1996-08-19 | 2007-10-30 | United States Of America As Represented By The Secretary, Department Of Health And Human Services | Liposome complexes for increased systemic delivery |
| US20030229040A1 (en) | 1997-03-21 | 2003-12-11 | Georgetown University | Cationic liposomal delivery system and therapeutic use thereof |
| US6977074B2 (en) | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| US6693086B1 (en) * | 1998-06-25 | 2004-02-17 | National Jewish Medical And Research Center | Systemic immune activation method using nucleic acid-lipid complexes |
| US20030022854A1 (en) * | 1998-06-25 | 2003-01-30 | Dow Steven W. | Vaccines using nucleic acid-lipid complexes |
| EP1146907A2 (en) | 1999-02-05 | 2001-10-24 | Genzyme Corporation | Use of cationic lipids to generate anti-tumor immunity |
| CA2363141C (en) | 1999-02-26 | 2010-04-06 | Novartis Vaccines And Diagnostics, Inc. | Microemulsions with adsorbed macromolecules and microparticles |
| JP4800485B2 (ja) * | 1999-03-26 | 2011-10-26 | バイカル インコーポレイテッド | ポリヌクレオチドベースのワクチンに対する免疫応答を増強するためのアジュバント組成物および方法 |
| US6852334B1 (en) * | 1999-04-20 | 2005-02-08 | The University Of British Columbia | Cationic peg-lipids and methods of use |
| JP5117648B2 (ja) * | 1999-04-20 | 2013-01-16 | ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア | カチオン性ｐｅｇ脂質および使用方法。 |
| US6649170B1 (en) * | 1999-05-12 | 2003-11-18 | Statens Serum Institut | Adjuvant combinations for immunization composition and vaccines |
| FR2794370B1 (fr) | 1999-06-03 | 2003-10-17 | Biovector Therapeutics | Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination |
| EP1185662B1 (fr) | 1999-06-10 | 2011-03-02 | Merial | Vaccins adn pour les chiens |
| CA2309313A1 (en) | 1999-08-05 | 2001-02-05 | Board Of Trustees Of The University Of Arkansas | Stimulation of the immune response by human dendritic cell manipulation |
| EP1214097B3 (en) | 1999-09-16 | 2011-07-20 | Eisai Inc. | Nucleic acids encoding polyepitope polypeptides |
| US20030008813A1 (en) * | 1999-12-17 | 2003-01-09 | Felgner Philip L. | Intracellular protein delivery compositions and methods of use |
| US20010026937A1 (en) | 2000-01-11 | 2001-10-04 | Juha Punnonen | Monocyte-derived dendritic cell subsets |
| EP1257565A4 (en) | 2000-02-01 | 2005-04-06 | Austin Research Inst | DERIVED FROM MUCIN-1 ANTIGENE AND ITS USE IN IMMUNOTHERAPY |
| WO2001080900A2 (en) | 2000-04-20 | 2001-11-01 | The University Of British Columbia | Enhanced stabilised plasmid-lipid particle-mediated transfection using endosomal membrane |
| AU2001297693A1 (en) | 2000-12-08 | 2002-09-12 | Coley Pharmaceutical Gmbh | Cpg-like nucleic acids and methods of use thereof |
| EP1355628A2 (en) | 2001-02-01 | 2003-10-29 | Board of Regents, The University of Texas System | Stabilised polymeric aerosols for pulmonary gene delivery |
| WO2002077012A2 (en) | 2001-03-23 | 2002-10-03 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Human papilloma virus immunoreative peptides |
| FR2824326B1 (fr) | 2001-05-04 | 2004-03-19 | Commissariat Energie Atomique | Melange de peptides issus des proteines e6 et/ou e7 de papillomavirus et leurs applications |
| US7025987B2 (en) | 2001-05-30 | 2006-04-11 | The Scripps Research Institute | Delivery system for nucleic acids |
| NZ530635A (en) | 2001-06-15 | 2007-03-30 | Nordic Vaccine Technology As | Therapeutical vaccination comprising an immunogen and a targeting vehicle comprising a carrier and a antigen silmilar to the first |
| FR2826293B1 (fr) | 2001-06-21 | 2004-01-30 | Elf Antar France | Procede d'obtention de gaz de synthese par oxydation catalytique partielle |
| CA2451846A1 (en) * | 2001-06-29 | 2003-01-09 | Chugai Seiyaku Kabushiki Kaisha | Cancer vaccine comprizing a cancer antigen based on the product of a tumor suppressor gene wt1 and a cationic liposome |
| JP2004534088A (ja) | 2001-07-06 | 2004-11-11 | スローン−ケッタリング・インスティテュート・フォア・キャンサー・リサーチ | 癌のための多価コンジュゲートワクチン |
| GB0118517D0 (en) | 2001-07-30 | 2001-09-19 | Mitsubishi Tokyo Pharm Inc | Compound |
| DE60238864D1 (de) | 2001-11-07 | 2011-02-17 | Mankind Corp | Für epitope von antigenen kodierende expressionsvektoren und verfahren zu deren konzeption |
| US7598421B2 (en) * | 2002-05-08 | 2009-10-06 | Ucl Biomedica Plc | Materials for the delivery of biologically-active material to cells |
| AU2003244855A1 (en) | 2002-07-05 | 2004-01-23 | Lipoxen Technologies Limited | Method to enhance an immune response of nucleic acid vaccination |
| WO2004014957A1 (en) * | 2002-08-12 | 2004-02-19 | The Council Of The Queensland Institute Of Medical Research | Novel immunogenic lipopeptides comprising t-helper and cytotoxic t lymphocyte (ctl) epitopes |
| US20050031587A1 (en) | 2002-10-04 | 2005-02-10 | Yamanouchi Pharmaceutical Co., Ltd. | Immune response induction method |
| AU2003284239B2 (en) | 2002-10-21 | 2008-08-21 | Eisai Inc. | Compositions and methods for treating human papillomavirus-mediated disease |
| SE0301109D0 (sv) | 2003-04-14 | 2003-04-14 | Mallen Huang | Nucleotide vaccine composition |
| JP2007500239A (ja) * | 2003-05-30 | 2007-01-11 | アルザ・コーポレーシヨン | 薬剤の肺投与の方法 |
| WO2005000889A1 (en) | 2003-06-05 | 2005-01-06 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Immunogenic peptides for the treatment of prostate and breast cancer |
| US8242089B2 (en) | 2003-06-18 | 2012-08-14 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Sphingolipids polyalkylamine conjugates for use in transfection |
| US7906122B2 (en) | 2003-06-18 | 2011-03-15 | Yissum Research Development Company Of The Hebrew University Of Jersusalem | Sphingoid polyalkylamine conjugates for Hepatitis B virus vaccination |
| US8592197B2 (en) | 2003-07-11 | 2013-11-26 | Novavax, Inc. | Functional influenza virus-like particles (VLPs) |
| WO2005014110A1 (en) * | 2003-07-22 | 2005-02-17 | Cytos Biotechnology Ag | Cpg-packaged liposomes |
| JP5097400B2 (ja) | 2003-09-03 | 2012-12-12 | デンドリセラピューティクス、インク． | 複合ワクチン |
| US20050112559A1 (en) | 2003-09-29 | 2005-05-26 | The Chinese University Of Hong Kong | Compositions and methods for diagnosing and preventing severe acute respiratory syndrome (SARS) |
| SG133594A1 (en) | 2003-12-10 | 2007-07-30 | Canji Inc | Methods and compositions for treatment of interferon-resistant tumors |
| CN1559607A (zh) | 2004-02-20 | 2005-01-05 | �й�ũҵ��ѧ | 一种核酸物质与蛋白质类组合物及其生产方法和在免疫调节中的应用 |
| WO2005097181A1 (en) | 2004-04-05 | 2005-10-20 | Pfizer Products Inc. | Microfluidized oil-in-water emulsions and vaccine compositions |
| GB0716992D0 (en) | 2007-08-31 | 2007-10-10 | Immune Targeting Systems Its L | Influenza antigen delivery vectors and constructs |
| US7303881B2 (en) * | 2004-04-30 | 2007-12-04 | Pds Biotechnology Corporation | Antigen delivery compositions and methods of use |
| EP1781593B1 (en) * | 2004-06-07 | 2011-12-14 | Protiva Biotherapeutics Inc. | Cationic lipids and methods of use |
| KR20070052273A (ko) | 2004-06-30 | 2007-05-21 | 아이디 바이오메디컬 코포레이션 오브 퀘벡 | 코로나바이러스 감염의 치료를 위한 백신 조성물 |
| US20060051405A1 (en) * | 2004-07-19 | 2006-03-09 | Protiva Biotherapeutics, Inc. | Compositions for the delivery of therapeutic agents and uses thereof |
| GB0417430D0 (en) | 2004-08-05 | 2004-09-08 | Uc3 | A novel HPV vaccine comprising peptides from host cell proteins |
| DE102004057303A1 (de) | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
| CA2589992C (en) | 2004-12-13 | 2014-04-22 | Peplin Research Pty Ltd | Treatment of solid cancers |
| US20060159738A1 (en) | 2004-12-14 | 2006-07-20 | Applera Corporation | Cationic liposomes and methods of use |
| KR20080012825A (ko) | 2005-01-21 | 2008-02-12 | 인트로겐 테라페티스, 인코퍼레이티드 | 표적 세포가 치료적 및 예방적 핵산에 지속 노출되게 하는국소 투여 |
| WO2007149062A2 (en) * | 2005-03-14 | 2007-12-27 | Board Of Regents, The University Of Texas System | Bioactive fus1 peptides and nanoprticle-polypeptide complexes |
| JP4516147B2 (ja) | 2005-03-18 | 2010-08-04 | ヴェーデクス・アクティーセルスカプ | 補聴器用遠隔制御システム |
| EP1882031B1 (en) | 2005-04-08 | 2017-11-08 | Argos Therapeutics, Inc. | Dendritic cell compositions and methods |
| EP1877088B1 (en) | 2005-04-11 | 2014-12-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Vaccine against pandemic strains of influenza viruses |
| US20060275777A1 (en) * | 2005-06-03 | 2006-12-07 | Waelti Ernst R | Novel strategies for protein vaccines |
| WO2007022152A2 (en) | 2005-08-15 | 2007-02-22 | The Research Foundation Of State University Of New York | Lipid nano particulates containing antigens as cancer vaccines |
| US20110305713A1 (en) | 2005-10-21 | 2011-12-15 | Medical College Of Georgia Research Institute, Inc | Methods and compositions to enhance vaccine efficacy by reprogramming regulatory t cells |
| JP5215865B2 (ja) | 2005-11-22 | 2013-06-19 | ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド | ノロウイルス抗原およびサポウイルス抗原 |
| US8802419B2 (en) | 2006-03-02 | 2014-08-12 | University Of Massachusetts | Modified pathogens for use as vaccines |
| JP2007238559A (ja) | 2006-03-10 | 2007-09-20 | Nagoya City Univ | 未成熟樹状細胞活性化剤及びその使用 |
| EP2013230A2 (en) | 2006-04-21 | 2009-01-14 | Transgene S.A. | Hpv-16-based papillomavirus vaccine |
| US20080014251A1 (en) | 2006-07-14 | 2008-01-17 | Advanced Vascular Dynamics | Hemostatic compound and its use |
| EP1894941A1 (en) | 2006-09-01 | 2008-03-05 | Institut Pasteur | Treatment of cervical carcinoma with a recombinant adenylate cyclase carrying HPV antigens |
| CA2700573C (en) | 2006-09-26 | 2016-11-22 | Cedars-Sinai Medical Center | Cancer stem cell antigen vaccines and methods |
| US20100099745A1 (en) | 2006-10-18 | 2010-04-22 | Suryaprakash Sambhara | Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors |
| KR100817024B1 (ko) | 2006-11-09 | 2008-03-26 | 재단법인 목암생명공학연구소 | 핵산 또는 약물을 간에 특이적으로 전달하는 복합체 및이를 포함하는 약학적 조성물 |
| US8877206B2 (en) | 2007-03-22 | 2014-11-04 | Pds Biotechnology Corporation | Stimulation of an immune response by cationic lipids |
| CA2688346A1 (en) | 2007-05-23 | 2008-12-04 | Vical Incorporated | Compositions and methods for enhancing immune responses to vaccines |
| EP2468763B1 (en) | 2007-05-31 | 2014-06-18 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | HPV epitopes targeted by T cells infiltrating cervical malignancies for use in vaccines |
| US7832751B2 (en) | 2007-06-29 | 2010-11-16 | Harley-Davidson Motor Company Group, Inc. | Rear fender assembly |
| JP5623910B2 (ja) | 2007-11-02 | 2014-11-12 | ザ ジョンズ ホプキンス ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ | ヒトパピローマウイルス感染症の治療又は予防のための複数型ｈｐｖペプチド組成物及び方法 |
| AU2009236306B2 (en) | 2008-04-17 | 2015-04-02 | Pds Biotechnology Corporation | Stimulation of an immune response by enantiomers of cationic lipids |
| WO2009142892A1 (en) | 2008-05-19 | 2009-11-26 | The University Of North Carolina At Chapel Hill | Methods and compositions comprising novel cationic lipids |
| US20100086584A1 (en) | 2008-09-18 | 2010-04-08 | Juvaris Biotherapeutics, Inc. | VACCINE COMPOSITIONS OF M2e, HA0 AND BM2 MULTIPLE ANTIGENIC PEPTIDES |
| CA2754826A1 (en) | 2009-03-06 | 2010-09-10 | Mount Sinai School Of Medicine | Live attenuated influenza virus vaccines comprising microrna response elements |
| JP5797190B2 (ja) | 2009-05-15 | 2015-10-21 | アイ アール エックス セーラピューティクス， インコーポレイテッド | ワクチン免疫療法 |
| WO2011109294A1 (en) | 2010-03-01 | 2011-09-09 | Dicerna Pharmaceuticals, Inc. | Lipid delivery formulations |
| CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| US9408914B2 (en) | 2010-04-28 | 2016-08-09 | Kyowa Hakko Kirin Co., Ltd. | Cationic lipid |
| AR087380A1 (es) | 2011-07-27 | 2014-03-19 | Baylor Res Inst | Vacunas de celulas dendriticas (cd) para la terapia del cancer de pancreas |
| ES2689799T3 (es) | 2011-09-12 | 2018-11-15 | Pds Biotechnology Corporation | Formulaciones de vacunas particuladas |
| EP2638896A1 (en) | 2012-03-14 | 2013-09-18 | Bioneer A/S | Cationic liposomal drug delivery system for specific targeting of human cd14+ monocytes in whole blood |
| EP2639299A1 (en) | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
| AU2013274235B2 (en) | 2012-06-15 | 2018-01-18 | Samir N. Khleif | Cationic lipid vaccine compositions and methods of use |
| AU2013317805B2 (en) | 2012-09-21 | 2018-07-26 | Pds Biotechnology Corporation | Improved vaccine compositions and methods of use |
| SG11201510748PA (en) | 2013-08-21 | 2016-03-30 | Curevac Ag | Composition and vaccine for treating lung cancer |
| AU2014340201B2 (en) | 2013-10-23 | 2019-02-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | HLA-A24 agonist epitopes of MUC1-C oncoprotein and compositions and methods of use |
| CN104189897A (zh) | 2014-05-21 | 2014-12-10 | 深圳先进技术研究院 | 一种树突状细胞高效负载抗原的制备方法 |
| KR102668219B1 (ko) | 2015-03-16 | 2024-05-28 | 막스-델부뤽-센트럼 퓌어 몰레쿨라레 메디친 인 데어 헬름홀츠-게마인샤프트 | Mhc 세포 라이브러리를 이용하여 신규한 면역원성 t 세포 에피토프를 검출하고 신규한 항원-특이적 t 세포 수용체를 단리하는 방법 |
| CN105920599B (zh) | 2015-09-17 | 2020-02-11 | 武汉生物制品研究所有限责任公司 | 以阳离子脂质体dotap为佐剂的疫苗及其制备方法 |
| US11612652B2 (en) | 2015-11-13 | 2023-03-28 | Pds Biotechnology Corporation | Lipids as synthetic vectors to enhance antigen processing and presentation ex-vivo in dendritic cell therapy |
| WO2018067822A1 (en) | 2016-10-05 | 2018-04-12 | Pds Biotechnology Corporation | Methods to alter the tumor microenvironment for effective cancer immunotherapy |
| JP7165652B2 (ja) | 2016-10-05 | 2022-11-04 | ピーディーエス バイオテクノロジー コーポレイション | 新規ｈｐｖ１６非ｈｌａ拘束性ｔ細胞ワクチン、その組成物及び使用方法 |
| CN111655238A (zh) | 2017-12-05 | 2020-09-11 | Pds生物科技公司 | 用于刺激i型干扰素基因的包括阳离子脂质的方法和组合物 |
| CN111217918B (zh) | 2020-03-04 | 2020-11-10 | 中山大学 | 一种基于2,4-二氧四氢喋啶合酶的新型冠状病毒s蛋白双区域亚单位纳米疫苗 |
-
2008
- 2008-03-17 US US12/049,957 patent/US8877206B2/en active Active
- 2008-03-20 EP EP08799629.4A patent/EP2125011B1/en active Active
- 2008-03-20 WO PCT/US2008/057678 patent/WO2008116078A2/en not_active Ceased
- 2008-03-20 AU AU2008228798A patent/AU2008228798B2/en active Active
- 2008-03-20 ES ES08799629.4T patent/ES2562714T3/es active Active
- 2008-03-20 PL PL08799629T patent/PL2125011T3/pl unknown
- 2008-03-20 CN CN201710819740.1A patent/CN107670031A/zh active Pending
- 2008-03-20 JP JP2009554742A patent/JP2010522206A/ja active Pending
- 2008-03-20 EA EA200901270A patent/EA200901270A1/ru unknown
- 2008-03-20 CN CN200880017151A patent/CN101702882A/zh active Pending
- 2008-03-24 TW TW097110452A patent/TWI558412B/zh active
-
2013
- 2013-10-18 JP JP2013217819A patent/JP6211383B2/ja active Active
-
2014
- 2014-11-03 US US14/531,469 patent/US11911359B2/en active Active
-
2021
- 2021-07-22 US US17/383,104 patent/US20220031650A1/en not_active Abandoned
- 2021-07-22 US US17/383,182 patent/US20210346333A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20150093410A1 (en) | 2015-04-02 |
| JP2010522206A (ja) | 2010-07-01 |
| WO2008116078A9 (en) | 2008-11-20 |
| AU2008228798B2 (en) | 2014-05-15 |
| EP2125011B1 (en) | 2015-11-11 |
| US20210346333A1 (en) | 2021-11-11 |
| AU2008228798A1 (en) | 2008-09-25 |
| US8877206B2 (en) | 2014-11-04 |
| ES2562714T3 (es) | 2016-03-07 |
| WO2008116078A2 (en) | 2008-09-25 |
| CN107670031A (zh) | 2018-02-09 |
| CN101702882A (zh) | 2010-05-05 |
| EP2125011A2 (en) | 2009-12-02 |
| US20090017057A1 (en) | 2009-01-15 |
| WO2008116078A3 (en) | 2009-06-04 |
| TWI558412B (zh) | 2016-11-21 |
| JP6211383B2 (ja) | 2017-10-11 |
| JP2014058525A (ja) | 2014-04-03 |
| WO2008116078A8 (en) | 2009-07-16 |
| WO2008116078A4 (en) | 2009-10-15 |
| US20220031650A1 (en) | 2022-02-03 |
| EP2125011A4 (en) | 2010-04-07 |
| TW200902060A (en) | 2009-01-16 |
| US11911359B2 (en) | 2024-02-27 |
| EA200901270A1 (ru) | 2010-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2125011T3 (pl) | Stymulacja odpowiedzi immunologicznej przez lipidy kationowe | |
| IL208713A0 (en) | Stimulation of an immune response by enantiomers of cationic lipids | |
| IL233176A0 (en) | activation of an immune response | |
| GB201008267D0 (en) | Cationic lipids | |
| EP2419172A4 (en) | CRANIAL STIMULATION | |
| EP2567952A4 (en) | CATIONIC LIPID | |
| GB201006495D0 (en) | Sexual stimulator | |
| EP3431138C0 (en) | BRAIN STIMULATION | |
| TWM386892U (en) | Eye massager | |
| GB2487166A8 (en) | Novel parasite therapy | |
| PL2448600T3 (pl) | Związki ukierunkowane na kationoniezależny receptor mannozo-6-fosforanu | |
| GB0720486D0 (en) | Cationic lipids | |
| PL2297357T3 (pl) | Przewidywanie odpowiedzi na leczenie przeciwwirusowe | |
| EP2586336A4 (en) | VIBRATION SENSOR CHAIR | |
| ZA201105198B (en) | Improvements related to the manufacture of coil springs | |
| GB201101591D0 (en) | Houysehold appliance subassembly | |
| GB2476767B (en) | Method of modifying the immune response | |
| ZA201207199B (en) | Immune therapy | |
| EP2255823A4 (en) | GUT IMMUNE-STIMULATOR | |
| EP2341860A4 (en) | EYE THERAPY SYSTEM | |
| AU2010902717A0 (en) | Stimulating immune response | |
| GB201119736D0 (en) | Muscle stimulation | |
| HK1160006A (en) | Priming of an immune response | |
| AU2011902292A0 (en) | The Stimulation Pad | |
| HK1182319A (en) | Methods for inducing an immune response |